Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Betta Pharmaceuticals Co., Ltd."
Count: 73
Selected: 0
| NCT ID | Title |
|---|
| NCT03222622 | Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis | ||
| NCT02801435 | Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis | ||
| NCT05789602 | Phase 1 Study of BPI-460372 in Advanced Solid Tumor Patients | ||
| NCT05341583 | Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer | ||
| NCT05433480 | A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer | ||
| NCT05369312 | Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients | ||
| NCT05341557 | A Phase 1 Study of BPI-371153 in Subjects With Advanced Solid Tumors or Relapsed/Refractory Lymphoma | ||
| NCT05316259 | A Food-Effect Study of BPI-16350 in Healthy Subjects | ||
| NCT03791112 | A Phase I Study of BPI-16350 in Patients With Advanced Solid Tumor | ||
| NCT05341570 | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668 | ||
| NCT05329298 | A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors | ||
| NCT05315180 | A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors | ||
| NCT05302843 | A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors | ||
| NCT02044328 | Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation | ||
| NCT04930432 | Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors | ||
| NCT02959619 | Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK | ||
| NCT05007938 | Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer | ||
| NCT02478866 | Safety and Pharmacokinetics of BPI-9016M in Patients With Advanced Solid Tumors | ||
| NCT02929290 | Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC | ||
| NCT02448797 | Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation | ||
| NCT04946890 | A Study of MRX2843 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | ||
| NCT04464551 | The Absorption, Metabolism and Excretion of [14C]D-0316 in Human | ||
| NCT04206072 | D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC | ||
| NCT04415320 | X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases | ||
| NCT03608007 | X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement | ||
| NCT04058704 | A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy | ||
| NCT03536481 | Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers | ||
| NCT03510611 | A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers. | ||
| NCT02914990 | Safety, Tolerability and Pharmacokinetic Profile of BPI-15086 in EGFR T790M Mutation-positive NSCLC Patients | ||
| NCT01855854 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | ||
| NCT01719536 | Icotinib Versus First-line Chemotherapy Plus Maintenance Treatment in EGFR Positive Lung Adenocarcinoma Patients | ||
| NCT02726568 | High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases | ||
| NCT03804541 | The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human | ||
| NCT03188848 | Dose Escalating Study of BPI-3016 in Healthy Subjects | ||
| NCT03754530 | Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation | ||
| NCT03749213 | Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer | ||
| NCT03396185 | Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer | ||
| NCT03349203 | Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer | ||
| NCT02125240 | Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma | ||
| NCT03215693 | X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib | ||
| NCT03346811 | Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer | ||
| NCT02404675 | High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation | ||
| NCT02574091 | Icotinib Hydrochloride Cream in Healthy Adults and Psoriasis Patients | ||
| NCT01665417 | Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma | ||
| NCT02544789 | Clofarabine in Chinese Pediatric Patients With Refractory or Relapsed Acute Lymphoblastic Leukemia | ||
| NCT01707329 | Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment | ||
| NCT01646450 | First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients | ||
| NCT02062515 | Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency | ||
| NCT02024633 | Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer | ||
| NCT01926171 | Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases |
